Literature DB >> 20551409

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Elliott C Dasenbrook1, William Checkley, Christian A Merlo, Michael W Konstan, Noah Lechtzin, Michael P Boyle.   

Abstract

CONTEXT: The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in the respiratory tract of individuals with cystic fibrosis (CF) has increased dramatically; however, its impact on outcomes in CF is unclear. Because the time between infection with bacteria in CF and death can be decades, observational studies with long periods of follow-up are well suited to address the current gap in knowledge.
OBJECTIVE: To determine whether isolation of MRSA from the respiratory tract of CF patients is associated with worse survival compared with patients who never have a culture positive for MRSA. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 19,833 CF patients aged 6 to 45 years seen at centers accredited by the Cystic Fibrosis Foundation in the United States. Patients entered between January 1996 and December 2006 and were followed up through December 2008. Cox regression models with time-varying covariates were used to compare survival between CF patients with and without respiratory tract MRSA. MAIN OUTCOME MEASURE: Time from age at entry until age at death from any cause.
RESULTS: In 137,819 patient-years of observation (median, 7.3 years/patient), 2537 CF patients died and 5759 patients had MRSA detected. The mortality rate was 18.3 deaths (95% confidence interval [CI], 17.5-19.1) per 1000 patient-years in patients without MRSA and 27.7 deaths (95% CI, 25.3-30.4) per 1000 patient-years in those with MRSA. Among those with MRSA, the attributable risk percentage of death associated with MRSA was 34.0% (95% CI, 26.7%-40.4%). The unadjusted hazard ratio associated with MRSA was 1.47 (95% CI, 1.32-1.62). After adjustment for time-varying covariates associated with severity of illness, MRSA remained associated with a higher risk of death (1.27; 95% CI, 1.11-1.45).
CONCLUSION: Detection of MRSA in the respiratory tract of CF patients was associated with worse survival.

Entities:  

Mesh:

Year:  2010        PMID: 20551409     DOI: 10.1001/jama.2010.791

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  104 in total

1.  Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.

Authors:  Rebecca A Keel; Andre Schaeftlein; Charlotte Kloft; J Samuel Pope; R Frederic Knauft; Marianne Muhlebach; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Antibiofilm Efficacy of Nitric Oxide-Releasing Alginates against Cystic Fibrosis Bacterial Pathogens.

Authors:  Mona Jasmine R Ahonen; Jamie M Dorrier; Mark H Schoenfisch
Journal:  ACS Infect Dis       Date:  2019-06-11       Impact factor: 5.084

Review 3.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

4.  Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient.

Authors:  Leah Molloy; Ashley Hall Snyder; Ruma Srivastava; Michael J Rybak; Eric McGrath
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

Review 5.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

6.  Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient.

Authors:  Caroline Rouard; Fabien Garnier; Jeremy Leraut; Margaux Lepainteur; Lalaina Rahajamananav; Jeanne Languepin; Marie-Cécile Ploy; Nadège Bourgeois-Nicolaos; Florence Doucet-Populaire
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  Gender differences in outcomes of patients with cystic fibrosis.

Authors:  Cayce L Harness-Brumley; Alan C Elliott; Daniel B Rosenbluth; Deepa Raghavan; Raksha Jain
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

8.  Update on Epidemiology and Treatment of MRSA Infections in Children.

Authors:  Michael Z David; Robert S Daum
Journal:  Curr Pediatr Rep       Date:  2013-09-01

9.  Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.

Authors:  Erin J McDade; Jennifer L Hewlett; Siby P Moonnumakal; Carol J Baker
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

Review 10.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.